Overview
’Metabolic Acidosis- Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, along with historical and forecasted Metabolic Acidosis epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.

Metabolic Acidosis Understanding
Acid–base disorders, comprising of metabolic acidosis, are disturbances in the homeostasis of plasma acidity. Distinct acidosis can be characterized by a process that increases serum hydrogen-ion concentration. The term acidemia is used to define the total acid–base status of the serum pH. For example, a patient can have multiple acidosis contributing to a net acidemia. It is categorized, based upon its origin as either a respiratory acidosis that involves changes in CO2 level, or metabolic acidosis, which is influenced by bicarbonate (HCO3).

Metabolic acidosis is defined by an increase in the hydrogen-ion concentration in the systemic circulation, which results in a serum HCO3 <24 mEq/L. It is not a benign condition and shows an underlying disorder that needs to be corrected to minimize morbidity and mortality. The many etiologies of metabolic acidosis are classified mainly into four mechanisms: acid ingestion, increased production of acid, decreased excretion of acid, and renal or gastrointestinal (GI) bicarbonate losses.

Metabolic acidosis can be acute or chronic. Acute metabolic acidosis is comparatively more common among severely ill patients than chronic metabolic acidosis. The frequency of chronic metabolic acidosis might increase with the expected rise in chronic kidney disease (CKD) in the geriatric population. Metabolic acidosis, acute or chronic, can have adverse effects on cellular function and can contribute to increased morbidity and mortality.

Epidemiology Perspective 
Metabolic acidosis epidemiology segment provides insights about historical and current metabolic acidosis patient pool and forecasted trends for 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Metabolic Acidosis Detailed Epidemiology Segmentation
The total prevalent cases of metabolic acidosis patients were found to be more in males than in females in 10EM during the study period 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Metabolic Acidosis epidemiology segmented as Total Prevalent Population of CKD patients, Total Prevalent Population of Metabolic Acidosis in CKD patients, Gender-Specific Diagnosed Population of Metabolic Acidosis, Total Diagnosed Population of Metabolic Acidosis, and Total Treated Population of Metabolic Acidosis in 10EM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, Brazil, China, and Mexico from 2017 to 2030.

Country Wise Metabolic Acidosis Epidemiology
The epidemiology segment also provides the metabolic acidosis epidemiology data and key findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.

  • As per we estimate, the total prevalent cases of CKD patients in 10 EM were 263,018,799 in 2017, which are expected to reach a significantly high number by 2030.
  • As per our analysis, the total prevalent cases of metabolic acidosis in China was found to be 8,881,796 in 2017, which are expected to reach a significantly high number by 2030.
  • As per our analysis, in the year 2017, the gender-specific diagnosed cases of metabolic acidosis in Germany were 194,037 in males and 158,757 in females, which are expected to reach a significantly high number by 2030.


Scope of the Report

  • The Metabolic Acidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Metabolic Acidosis Report and Model provide an overview of the risk factors and global trends of Metabolic Acidosis in the 10 emerging markets the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.
  • The report provides insight about the historical and forecasted patient pool of metabolic acidosis in the 10 emerging markets the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.
  • The report helps to recognize the growth opportunities in the 10EM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of metabolic acidosis.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Prevalent Population of CKD patients in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Prevalent Population of Metabolic Acidosis in CKD patients in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Gender-Specific Diagnosed Population of Metabolic Acidosis in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Diagnosed Population of Metabolic Acidosis in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Treated Population of Metabolic Acidosis in 10EM.



Report Highlights

  • 12-Year Plus Forecast of Metabolic Acidosis epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of Metabolic Acidosis
  • Prevalent Cases according to segmentation: Gender-specific
  • Diagnosed cases of Metabolic Acidosis
  • Treated cases of Metabolic Acidosis


KOL-Views
We interview KOLs and SME’s for their opinion through primary research to fill the data gaps and validate our secondary research; this helps to understand the total patient population and current diagnosis pattern. It will support the clients in identifying the epidemiology scenario of the indication.

Key Questions Answered

  • What will be the growth opportunities in the 10EM with respect to the patient population pertaining to Metabolic Acidosis?
  • What are the key findings pertaining to the Metabolic Acidosis epidemiology across 10EM and which country will have the highest number of patients during the study period (2017–2030)?
  • What would be the total number of patients of Metabolic Acidosis across the 10EM during the study period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 10EM during the study period (2017–2030)?
  • What is the disease risk, burden and unmet needs of Metabolic Acidosis?
  • Which diagnosis strategy is followed and suggested by the healthcare experts?



Reasons To Buy
The Metabolic Acidosis Epidemiology report will allow the user to:-

  • Develop business strategies by understanding the trends shaping and driving the Global Metabolic Acidosis Epidemiology.
  • Quantify patient populations in the Global Metabolic Acidosis Epidemiology to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for the regions covered.
  • Understand the magnitude of Metabolic Acidosis population by its severity.
  • The Metabolic Acidosis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Metabolic Acidosis Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 12-year plus forecast period using reputable sources.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


Geographies Covered

  • The United States


 EU5 (Germany, France, Italy, Spain, and the United Kingdom)

  • Japan
  • Brazil
  • China
  • Mexico


Study Period: 2017–2030